

Index

- 1000 genomes project
112–116
- 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE)
132
- 2,3,7,9 tetrachlorodibenzo-p-dioxin (TCDD)
466–467 (*See also* TCDD and Dioxin)
- 24-hour recall
190
- 32P-post-labeling assay
49–57
- 8-hydroxy-2'-deoxyguanosine (8-OHdG)
354, 393–394, 464
- 8-oxodG
194
- Accelerator mass spectrometry (AMS)
49, 53
- Acquired (adaptive) immunity
216–233
- Additive interaction
294–298
- Adductomics
495
- Adipokines
193, 199–201
- Adiponectin
200–205, 369, 442–447
- Adipose tissue
199, 201, 205, 442–448
- Aflatoxin (AFB1)
52, 55–56, 68, 192, 340
- Airways diseases
395–399, 481
- Albumin adducts
55–56
- Aliquoting
30–32
- Allele
 - based analyses, 289–290
 - specific PCR, 78 (*See also* Polymerase chain reaction)
- Alzheimer's disease (AD)
407–419
- Amyotrophic lateral sclerosis (ALS)
410–411
- Analysis of GWAS data
19, 290–293, 351, 367
- Analytical variability
31, 167
- Androgens
193, 201
- Aneuploidy
68, 82, 104, 319, 489, 464
- Antibody arrays
128–129
- Antigen detection
175–176
- ApoE genotypes with LDL-C
377–378
- Arbitrarily-primed PCR (AP-PCR)
181
- Aromatic amines
53–55, 171–172
- Arrayed primer extension (APEX)
75, 77, 80–81
- Arsenic and urothelial cancer
342
- Asbestos-associated fibrosis (asbestosis)
388
- Asia cohort consortium
250
- Association studies
106, 116, 261–280
using families (*See* Family-based association studies)
- Asthma
220, 224, 233, 272–279,
395–397, 475–488
- Atherosclerosis
443–444
- Atomic absorption (AA)
46
- Attenuation bias
164
- Autoantibodies
225–226, 230–233
- Autoimmune disorders
223
- Automated systems
32–34
- Bacterial plasmid analyses
181
- Barker hypothesis
462 (*See also* Developmental origins)
- Banking specimens
12
- Bayesian approach
265, 291, 326
- B-cells
217–218
malignancies, 226
- Bead-array technology
109
- BeadArray platforms
123
- BEAMing
80
- Benzene
83, 84, 125, 129, 170, 171, 172,
243, 245
and leukaemia, 341–342
- Berylliosis
390
- Bias
143–161
in prevalence surveys, 186
in the magnitude of the
association, 186
- Biobanks
90, 498

- Biochemical biomarkers
 - 219
- Bioinformatics
 - 37, 115, 121–141, 498–499
- Biological plausibility
 - 327–328
- Biomarker
 - characteristics, 165
 - validation, 350–351
 - validity, 167
 - of effect, 44, 304
 - of exposure, 44, 190–196, 304
 - of susceptibility, 44, 304
- Biomarkers
 - analysis of genetic variation, 99–120
 - analytical methods, 43–62
 - assessment of genetic damage, 63–98
 - biosample management, 23–42
 - cellular –, 216
 - Consortium, 317
 - measurement errors, 143–162
 - of absolute intake, 190–196
 - of correlated intake, 190–196
 - of female and male puberty, 453–457
 - of female reproductive function, 456–459
 - of fetal and infant development, 459–460
 - of intermediate endpoints, 193
 - of internal dose, 43–57
 - of male reproductive function, 462–465
 - of obesity and cancer, 446–447
 - platforms for analysis, 121–142
- Biorepository
 - 24–39, 113–114
- Biosafety
 - 38
- Biospecimen
 - collection, processing, and storage, 34, 40, 190, 241–242, 247–253
 - resource, 23
- Bisphenol A
 - 462
- Blood
 - 26, 27–33, 125, 132, 166, 170, 202, 203–204, 243, 306
 - pressure, 363, 367–379
- Body mass index (BMI)
 - 201, 276, 342, 376
- Breast cancer
 - 51–53, 126, 132, 133, 146, 156, 193, 194, 200–201, 263, 308, 314–319, 447, 496
- Bronchiolitis obliterans syndrome (BOS)
 - 387, 388, 397–399
- C-reactive protein (CRP)
 - 374, 375
- Canalization
 - 375 (*See also* Developmental adaptation)
- Cancer
 - 337–362
- Candidate
 - plasma biomarkers in CHD, 367
 - susceptibility genes and investigation, 341, 410, 461
- Capillary electrophoresis
 - 49, 88, 110, 123, 130
- Carcinoembryonic antigen (CEA)
 - 225, 308, 389
- Carcinogen–DNA adducts
 - 49–57, 481
- Case–cohort design
 - 248–249, 282
- Case–control design
 - 250–251, 282
- Case-only and other study designs
 - 255–256, 285, 296, 461
- Causality
 - 184–185, 338–339, 351
- CCR5 receptor
 - 393, 438
- CD3
 - 217
- CD4
 - 217–221
- CD8
 - 218, 221
- CD19
 - 218
- CD36
 - 445–446
- CD45
 - 218, 228, 229
- Cell culture systems
 - 182
- Cellular biomarkers (*See* Biomarkers)
- Centers for Disease Control and Prevention (US)
 - and blood spot cards, 30
 - and integration of genetic variation in population-based research, 13
 - information management at the –, 37
 - NHANES, 165
 - PulseNet, 424
- Central melanocortin system
 - 442
- Cerebrovascular disease
 - 443
- Cervical cancer
 - 183, 184, 186, 310, 432
- CFSUM1 and 2
 - 133
- Chemotherapy
 - 52, 85, 169, 308, 310–315, 435
- Childhood cancer
 - 347, 454, 461, 475, 481
- Children
 - 478–492
- Chlamydomydia pneumoniae
 - 434
- Cholecystokinin
 - 442
- Cholesterol
 - 102, 155, 441 (*See also* High-density lipoprotein cholesterol, Low-density lipoprotein cholesterol, Total cholesterol)
 - and colon cancer, 154
 - and CHD mortality, 370, 371
 - as a marker of intermediate endpoints, 193
 - dietary –, 378
 - LDL –, 244, 363, 366
 - HDL –, 342
 - total –, 375
- Chromatin immunoprecipitation (ChIP)
 - 113, 126, 495
- Chromosome aberrations
 - 73, 81–85, 353, 355
- Chronic
 - beryllium disease (CBD), 387–391
 - lymphocytic leukemia (CLL), 226–227
 - obstructive pulmonary disease (COPD), 388, 397–399
- Circadian rhythm
 - 206
- Classification and regression tree (CART)
 - 297

- Clinical
 - endpoint, 308, 311
 - medicine, 303–319
 - treatment, 421–434
 - trials, 310–312
- Clonal expansion
 - 217, 218, 222, 223, 227
- Cluster of differentiation (CD) number
 - 216, 389
- Clustering
 - Bayesian –, 291
 - familial –, 364
 - genotype –, 285, 286, 287
 - behaviour, 131
 - for classification, 135
- Coal workers' pneumoconiosis (CWP)
 - 387, 391–393, 394, 399
- Coefficient of variation
 - 158, 167, 209, 462
- Cohort
 - consortium, 248
 - Asia –, 250
 - NCI –, 351
 - design, 246, 248, 256, 263
 - studies, 245
- Collaboration
 - 330
- Comet assay
 - 354, 394, 464
- Commensals and pathogens
 - 426, 434–435
- Common rule
 - 13, 14
- Communicating test and study results
 - 10, 14, 15–17, 486–487
- Comparative genome hybridization (CGH)
 - 123, 306, 319, 348
- Complement fixation
 - 219–220
- Complex phenotypes
 - 272
- Concentration biomarkers
 - 190, 196
- Confidentiality of data
 - 10, 14, 15, 19, 116, 264, 467, 483, 486
- Confounding
 - 11, 16, 184, 225, 253, 268, 272, 273, 291, 326, 327, 329, 345, 349, 350, 351, 370, 373, 375, 443, 461
- Conicity index
 - 448
- Consortia
 - 323, 330
- Copy number variations (CNVs)
 - 103–104
- Coronary heart disease (CHD)
 - 363–379
- Correlated error
 - 157–159
- C-reactive protein
 - 193, 197, 221, 369, 372, 374, 375, 448
- Cross-sectional studies
 - 169, 242–245, 351, 447, 495, 496
- CRP (See C-reactive protein)
- Cryopreservation
 - 31, 33, 249, 251, 253
- Cultivation
 - 175, 176, 177, 179
 - assays, 181–182
- Cysteine
 - 131
- Cytokine IL17
 - 218
- Cytokines
 - 220, 443, 481
- Data
 - base for SNPs, 102
 - mining methods, 297–298
 - normalisation, 134
 - standardization, 330
- dbSNP (See Database for SNPs)
- Dementia
 - 408, 412
- Dermal exposures
 - 477
- DES
 - 460
- Design issues
 - 146, 346, 351
- Detection of mutations
 - 74–78
- Developmental adaptation
 - 375 (See also Canalization)
 - defect, 123, 476
 - disorders, 232, 454, 460, 461, 475, 493
 - exposures, 477
 - origins, 462 (See also Barker hypothesis)
 - studies, 25
 - toxicity, 464, 477, 482, 483
- Diabetes
 - 200, 201, 247, 319 (See also Type 1 –, Type 2–, TEDDY)
- Diagnostics
 - 130, 303, 305, 308, 438
- Diagnostics prenatal
 - 82
- Diesel exhaust
 - 172, 479
- Dietary
 - antioxidants, 194, 408
 - biomarkers, 195, 196
 - factors, 107, 189, 378
- Difference gel electrophoresis (DIGE)
 - 127
- Differential
 - measurement error, 144, 145, 146, 147, 150, 154, 155, 159
 - misclassification, 150, 169, 246, 251, 252, 285, 286, 328
- Diffusion-sink device
 - 205
- Dimension reduction
 - 134, 297
- Dioxins
 - 165, 218, 243, 252, 462, 466–467 (See also TCDD)
- Disease course
 - 45, 303, 350, 421, 434, 435
- Disease susceptibility locus (DSL)
 - 264, 271, 283
- Disorders of the immune system
 - 223
- DNA
 - adducts in excretion, 52
 - and protein adducts, 48, 56, 57, 192
 - damage, 52, 63, 65, 66–71, 86, 194–196, 339, 344, 345, 347, 350, 353, 354, 464, 482
 - diagnostics, 126
 - extraction, 31–32, 75, 76, 178, 282, 286
 - microarrays, 124, 126, 128, 129
 - repair, 341, 343, 344, 345, 353, 355, 477, 481, 494
 - sequencing, 74, 89, 111–112, 121–124
- Dose-response models
 - 352
- Doubly labelled water
 - 195
- Dried blood spot (DBS)
 - 175, 176, 227, 459
- Drug
 - development, 130, 310, 311–312, 315, 317, 319
 - discovery, 310–311
- Duplicates
 - 105, 108, 110, 114, 285, 287
- Elston-Stewart algorithm
 - 265–266

- Endocannabinoids
442
- Endogenous
DNA damage, 52 (*See also* DNA damage)
hormones, 27, 33, 190, 200 (*See also* Hormones)
- Environmental
163–174, 337
exposures, 172, 230, 254, 343, 345, 456, 460, 475, 483, 494, 497
exposure markers, 170
neurotoxicants, 410
tobacco smoke (ETS), 54, 170–171, 347, 352, 477, 481
- Enzyme-linked immunosorbent assay (ELISA)
49, 53, 55, 57, 148, 149, 183, 390
- EPIC-Heart
378
- Epidemiology of infectious diseases
422, 426, 427
- Epigenetic mechanisms
462
- Epigenetics
348–353
- Estrogens
53, 200, 201, 205, 412, 457
- Ethical issues
9–22, 10, 460, 483, 488
- Ethnicity
291, 293, 346, 365, 368, 441, 457
- ETS exposure (*See* Environmental tobacco smoke)
- European Prospective Study Into Cancer and Nutrition (EPIC)
191, 339, 342, 345, 352, 378
- Evaluation of interactions
295, 296
- Exogenous hormones
199, 200
- Exposome
172, 494
- Exposure
assessment, 11, 163, 165, 169, 172, 241, 246, 251–252, 256, 285, 294, 345, 392, 413, 461, 466, 494, 499
assessment and misclassification, 246
biomarkers, 22, 165, 190, 196, 243, 252, 305, 411, 415, 465
in utero, 230, 347, 354, 460, 461, 462, 465, 475, 476, 478, 481, 488
variability, 167–168
- Expression profiling
113, 124, 125, 126, 331, 497
- F2-isoprostane
444, 445
- Family-based
association studies, 268, 273, 274, 276
association tests, 269, 277
designs, 261–280, 327
- FBAT approach
269–277
- FBAT-GEE statistic
273
- Federal Drug Administration (US FDA)
310, 313, 317, 318
biomarkers approved by the –, 308
list of valid genomic biomarkers, 309
- Female libido
456
- Fetal and infant development
459–460
- Fetal lung maturation
459
- FEV1
273, 398, 479
- Fibrinogen studies collaboration
371, 372, 373, 374
- Field validation
350
- Finger prick
203, 204
- Fingerprint
carcinogen –, 67, 72, 340
gene –, 114, 222, 285, 340, 422, 423
- Fixed effects models
326 (*See also* random effects)
- FlexTree method
298
- Flow cytometry
80, 89, 216, 217, 218, 227, 389, 464
- Fluorescence in situ hybridization (FISH)
66, 82, 83, 124, 315, 341, 464
- Fold change
125, 127, 134
- Follicle stimulating hormone (FSH)
455
- Follow-up of cases to determine clinical outcomes
250, 251, 254
- Food frequency questionnaires (FFQ)
189, 190, 191, 194, 195–196
- Foodborne outbreak
423
- Forward phase arrays
128
- Fourier transform infrared (FTIR)
130
- Framingham
276, 367, 375, 444
- Fungal carcinogens
68, 192, 340
- Future use of specimens
12, 13, 31, 37, 460
- Gail model
496
- Gas chromatography (GC)
48, 130, 133, 466, 467
- Gender
346–347
- Gene
expression profiling, 113, 124, 125, 126, 331, 497
fingerprint (*See* Fingerprint)
methylation, 66
-environment interactions, 277, 281–302, 342, 397, 410, 460
-gene interaction, 255, 281, 285, 299, 301, 410
- Genetic
algorithm (GA), 135, 105, 265, 266
and lifestyle factors, 377–378
biomarkers, 222–223, 231, 306, 317, 332, 391
lineages, 427, 429, 430, 432
linkage analysis, 261, 264–266, 388, 395, 410
polymorphisms, 102, 112, 281, 282, 344, 399, 412, 413, 415, 448
susceptibility, 230, 252, 255, 281, 282, 287, 303, 343, 352, 355, 443, 445–447, 467, 478
susceptibility loci, 264, 271, 281, 282, 283, 287, 293, 336, 359
testing, 256, 307, 318, 319, 391
variation, 99–120, 194, 199, 209, 252, 281–302, 324, 364, 494, 495

- Genome
 99–120, 122, 123, 136, 137, 172, 193, 196, 248, 265, 282, 283, 319, 332, 346, 348, 430, 431, 494, 496, 497
 scan meta-analysis (GSMA), 332
 -wide association studies (GWAS), 19–20, 99–120, 194, 264–280, 324–330, 338, 346, 348, 367, 438, 448, 454, 494 (See also Meta-analyses)
 -wide association studies of BM, 448
- Genomic
 amplification, 124, 175, 178, 180
 approaches, 365
 imprinting, 306, 465
- Genomics
 4, 28, 88, 113, 121–142, 317, 319, 324, 333, 355, 495, 496
- Genotoxic compounds
 50, 52, 74, 86, 195, 244, 317, 339, 344, 464, 477, 478, 488
- Genotype
 analysis, 108–109
 -based analyses, 288–290
- Genotypic risk ratio
 262
- Genotyping
 88, 102–123, 180–182, 252, 265–268, 281–287, 323, 324, 327, 329, 330, 343, 345, 367, 411, 460
- Gestational neuroimmunopathology (GENIP) hypothesis
 232–233
- Ghrelin
 442
- Glutathione
 68, 131, 343, 394, 478, 480
 peroxidase 1, 393–394, 444, 445
- Glycemic status
 376
- Half-lives
 165–168, 192, 455, 461
- Haplotype
 analyses, 269–272, 281, 290, 313
 blocks, 103, 268
 mapping, 122–123
 phase, 102, 271
 tagging SNPs (htSNPs), 268
- Haplotypes
 103, 122, 230, 231, 265, 266, 267–271, 290
- Hardy-Weinberg equilibrium
 105, 286
- HDL-C (See High-density lipoprotein cholesterol) (See also Cholesterol, Low-density lipoprotein cholesterol, Total cholesterol)
- Health Insurance Portability and Accountability Act (HIPAA)
 10, 13, 486
- Helper T-cells (See T-cells)
- Haemoglobin adducts
 54, 165, 170, 172, 173, 242, 347, 355
- Henle-Koch's postulates
 183, 422
- Hepatitis A
 182, 423, 424, 435
- Hepatitis B
 56, 178, 182, 340, 425, 433, 434, 435
- Hepatitis C
 178, 182, 425, 433, 434
- Herceptin
 314
- Heritability
 261, 282
- Herpes virus 8
 425, 432, 433, 434
- Heterocyclic amines (HCAs)
 191, 192
- Heteroduplex mobility assay (HMA)
 181
- Heterogeneity, 325–327
 disease –, 293, 414
 genetic –, 196
 etiologic –, 343, 255
- Heterogeneity-based genome search meta-analysis (HEGESMA)
 332
- Hierarchical-Bayesian methods
 293, 298
- High performance liquid chromatography (HPLC) (See Liquid chromatography)
- High-density lipoprotein cholesterol, 372, 374, 375
 SNP detection, 109–110, 267
- High-order interactions
 297–298
- High-throughput sequencing
 71, 80–81, 124, 126, 436, 496, 112, 121
- HIPAA (See Health Insurance)
- Historical cohort approach
 263
- HLA-DP β 1
 387, 391, 399
- Hormonal variation
 206
- Hormone assays
 204, 208
- Hormones
 199–213
- Hospital-based studies
 250, 251, 253, 254, 282, 287
- Host defence system
 176, 182, 216, 219, 220, 221, 224
- HPV serotypes 16 and 18
 435
- Huber-White variance correction procedure
 263
- HuGENet (See Human genome epidemiology network)
- Human
 chorionic gonadotropin (hCG), 457, 458, 459
 epidermal growth factor receptor 2 (HER2), 305, 312, 314, 315, 317
 genome epidemiology network (HuGENet), 324, 325, 327, 330
 immunodeficiency virus (HIV), 215, 429, 430, 432, 435, 438, 480
 leukocyte antigens (HLA) (See also HLA-P β 1), 221, 222, 230, 231, 438
 microbiome project (HMP), 113
 papillomavirus (HPV), 39, 178, 183, 184, 186, 187, 426, 432, 435
- I2
 325, 326, 329
- Identifiability of biological specimens
 14
- IgA
 220, 221
- IgD
 220
- IgE
 219, 220–224, 479, 481
- IgG
 182, 185, 220, 221, 232, 233, 306, 369
- IgM
 182, 185, 220, 221, 306

- Immune
 - biomarkers in animal models, 224
 - biomarkers of neurodevelopmental disorders, 232
 - deficiency disorders, 223–229
 - proliferative disorders, 224
 - reactive disorders, 223–224
 - system, 215–240
- Immunoaffinity chromatography (IAC) 48
- Immunoassays 48, 49, 53, 57, 177, 178, 183, 208, 218, 345
- Immunodiffusion 183
- Immunogenic exposures 223–224
- Immunoglobulin 219–226
- Immunohistochemistry (IHC) test 49, 57, 314, 315
- Immunopathology 216, 223, 232
- In utero* 230, 233, 347, 460, 461, 462, 465, 475–488
 - and childhood periods, 476, 477, 488
- Indirect detection (See Serological methods)
- Individual variability 167
- Inductively coupled plasma-optical emission spectrometer (ICP-OES) 46
- Infectious
 - causes of cancer, 175–188, 421, 433, 434
 - diseases, 175–188, 421–440
- Infertility/early pregnancy loss 200, 454, 456, 457–488
- Inflammation 216, 441–445
- Inflammatory biomarkers 44, 193
- Informatics 34–37
 - system security, 35–37
- Information
 - bias, 144, 326–327
 - management (See also Laboratory information management), 23–42
- Informed consent 12–13, 486
- Innate immunity 216, 221
- Institutional review board (IRB) 10–20, 486
- Insulin
 - resistance, 193, 200–201, 444–446
 - like growth factor I (IGF-I), 201, 209–210, 342
 - like growth factor binding protein 3 (IGFBP-3), 201, 210, 342
- Intake assessment methods 190
- Interleukins 218–220, 374, 389, 393
- Intermediate
 - biologic effects, 243–245
 - endpoints, 242–245
- International HapMap project 102, 104, 108, 110, 111, 116, 122, 283, 291
- International Agency for Research on Cancer (IARC)
 - biological resource centre guidelines, 27, 28, 29, 31
 - classification of carcinogens, 71
 - p53 database, 70, 73
- International Organization for Standardization (ISO) 38
- International Society for Biological and environmental repositories (ISBER)
 - best practices, 27, 28, 29, 31, 34, 37, 38
- Interpretation of biomarker data 16
- Interpreting the results 15, 327
- Interstitial lung diseases 388, 391, 399
- Intervention strategies 353–354, 434, 436, 479, 483
- Intraclass correlation coefficient 143, 155–157, 158, 159, 167, 209, 245
- Intramethod reliability 155–156
- Intrauterine growth retardation 459–460
- Inventory control 36
- Irinotecan 312–314
- Iron 191, 369, 389, 392
- Kadoorie prospective study in China 378
- Kaposi's sarcoma (KS) 425, 432, 433
- Kappa in reliability studies 143, 158
- Kin-cohort approach 263
- K-nearest neighbors (KNN) 135
- Laboratory information management system (LIMS) 110, 115
- Lab-on-a-chip 88–89, 96
- Lander-Green-Kruglyak (LGK) method 265–266
- Leptin 203, 342, 369, 442, 443, 444, 445, 447, 455
- Libido 454, 456, 462, 463
- Lifestyle exposures 373–378
- Linkage
 - analyses, 264–268, 276, 388, 398
 - disequilibrium (LD), 102–103, 106, 265, 267, 268, 272, 283, 327, 376
- Liquid chromatography (LC) 48, 75, 77, 79, 127, 130, 132
 - High performance – (HPLC), 48, 49, 52, 53, 54, 55, 57, 79, 132, 170
 - Ultra-performance – (UPLC), 130, 498
- Liver cancer 45, 47, 52, 56, 79, 192, 193, 226, 340, 341, 344, 434
- LOD score 264–266
- Logistical issues in children's studies 483
- Longitudinal investigation of fertility and the environment (LIFE) study 458
- Low-density lipoprotein (LDL-C) cholesterol 244, 363, 364, 366, 372, 375, 377, 408 (See also Cholesterol, High-density lipoprotein cholesterol, Total cholesterol)

- Low-level exposures
 - 352, 482, 499
- Lp-PLA2
 - 371, 372, 376
 - studies collaboration, 371
- Lung cancer
 - 56, 67, 86, 132, 171, 172, 226, 338–340, 347, 348, 349, 352, 353, 388, 390, 478, 481
- Luteinizing hormone (LH)
 - 455
- Lyme disease
 - 434
- Lymphocytes
 - 86, 217, 244, 253, 391, 394, 480
 - subsets, 217
- Lymphokines
 - 220, 221
- Major histocompatibility complex (MHC)
 - (transplantation) antigens, 221
 - genes, 222
- Malaria
 - 422, 432
- Male
 - hormones, 463
 - libido, 462–463
- Manganese superoxide dismutase (MnSOD)
 - 193
- Mapping by admixture of linkage disequilibrium (MALD) (*See also* Linkage disequilibrium)
 - 106
- Mass spectrometry (MS)
 - 48, 79, 124, 127–128, 495, 497
 - (*See also* Tandem – (MS/MS), 79, 127)
- Mast cells
 - 219
- Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF)
 - 87, 109, 128 (*See also* Surface-enhanced laser)
- Measurement error
 - 143–162, 184
- Measuring DNA adducts
 - 49–57
- Mechanisms of mutagenesis
 - 64–72
- Membrane EIAs
 - 177, 183
- Mendelian randomization
 - 373–375, 461
- Menstrual cycle
 - 205–206, 454, 456–457
- Mesothelioma
 - 388–390
- Meta-analyses
 - 323
 - of genome-wide association studies, 330–332 (*See also* Genome-wide association studies)
 - of individual participant data (MIPD), 329–330
- Metabolome
 - 122–123, 130, 497
- Metabolomics
 - 121, 129–133, 337, 497
- Methicillin resistant Staphylococcus aureus (MRSA)
 - 427, 428, 435
- Methyl mercury
 - 46, 460, 465
- Methylation
 - 86–88, 126, 348–349
- Methylenetetrahydrofolate reductase (MTHFR) gene
 - 88, 343–344
- Mexico City Prospective Study
 - 378
- Microarray
 - platforms, 104, 125, 129, 332, 431
 - based gene expression profiling, 331
- Microarrays
 - 83, 124, 125, 126, 128, 180, 219, 332–333, 350, 367, 431, 496
- Microbial genome
 - 180, 181
 - Program, 431
- Microbiota
 - 432, 436, 438
- Microfabricated genetic analysis systems
 - 88
- Micronuclei
 - 85–86, 351, 497
- Microsatellite
 - instability, 76, 86
 - panels, 265
- Microscopic examination
 - 82, 175–176, 463
- Minor allele frequency (MAF)
 - 101, 110, 283, 364, 377, 413
- Misclassification (*See also* Measurement error)
 - 147, 148, 150, 186, 246, 251
 - bias, 144
 - due to random within-person variation, 246
- Mitochondrial genome
 - 63, 73
- Mixtures of carcinogen exposure
 - 49, 190, 410, 456, 461, 499
- Mobile genetic elements
 - 424, 426, 427, 428–429, 436
- Model
 - of parallel tests, 156
 - dependent methods, 266, 267
 - free methods, 266, 273
- Molecular
 - cancer epidemiology, 337–338
 - epidemiology, 1, 1–7, 9–22, 323–324, 242
 - fingerprints, 421–423
- Monoclonal B-cell lymphocytosis (MBL)
 - 226–227
- Monte-Carlo Markov chain (MCMC) algorithms
 - 266
- Müllerian inhibiting substance (MIS)
 - 455
- Multidimensional protein identification technology (MuDPIT)
 - 124, 127
- Multi-factorial dimension reduction (MDR)
 - 297–298
- Multilocus haplotype
 - 271
- Multimarker
 - FBATs, 272
 - tagging, 283
- Multiple food records
 - 189
- Multiplicative interaction
 - 294–298, 467
- Multistage designs
 - 263, 274, 282, 284, 293, 352
- Multistep carcinogenesis
 - 72–74
- Mutation
 - patterns, 70–71
 - enriched PCR, 77–78 (*See also* Polymerase chain reaction)
- Mutations
 - 63–98
 - in mitochondrial DNA, 73
- Mycotoxins
 - 192, 410
- Myocardial infarction
 - 129, 364–367, 444, 445
- Nanotechnology
 - 388, 495, 496

- National Cancer Institute (US)
iv, 23, 27, 37, 194, 299, 308
informatics at the – , 37
Cancer genetic markers of
susceptibility (CGEMS),
194
FDG-PET, 308
- National Centers for Children's
Environmental Health
483, 488
- National children's study
462, 488
- National health and nutrition
examination Survey (NHANES)
47, 165, 166, 203, 444
- National Institute of Environmental
Health Sciences (NIEHS)
73, 137, 455, 483, 488
- Natural killer (NK) cell
217
- NBS (See Newborn bloodspot
screening)
- NCI cohort consortium
248, 351
- Nested case-control study
56, 148, 169, 251, 282, 339,
437
- Networks
pathways and –, 281, 298
consortia and –, 317, 324,
329–330, 355
transmission –, 426, 430
- Neurobehavioural disorders
233, 482–487
- Neurodegenerative disease
407–419
- Neuromental disorders (NMDs)
232, 233
- New infectious agents
176, 182, 421, 422, 428, 429,
432–433
- Newborn bloodspot screening
(NBS)
227
- Newborn screening
233, 307
for immune disorders, 216, 227
for Type 1 diabetes, 231
- NHANES (See National Health and
Nutrition)
- NMDs (See Neuromental disorders)
- Nondifferential misclassification
(See *also* Misclassification)
148–154, 246, 251
- Non-lymphoid cells
218
- Non-specific markers
171, 216, 220, 224
- Nuclear magnetic resonance
49, 57, 124, 130, 132, 133, 349,
498
- Nucleic acid detection
177–185
- Nurses health study
203, 415
- Nutrient intake
195
- Nutritional
factors, 342, 346–347, 354,
460, 478
status biomarkers, 189, 190
- Obesity
193, 200, 441–452
- Occupational carcinogen exposure
51–52
- “Omics”
122, 134–136, 319, 496–498
- “Omic” technologies
348–350, 497
- Open reading frames (ORFs)
431
- Opportunistic infection
435
- ORFs (See Open reading frames)
- Origin of an epidemic
426–427
- Outbreak investigations
422–426
- Oxidative
damage 353, 387, 393, 398
stress 194, 349, 388, 393, 394,
409, 410, 443–444, 464
– biomarker 8-oxoguanosine,
131
- p53
aflatoxin and –, 340
amplichip – microarray, 47
and apoptosis, 394
and asbestos exposure, 389–
390
autoantibodies, 389–390
mutations, 71, 76, 305, 339,
341, 351
smoking and –, 51
- PAH-DNA adducts
50, 51, 56, 195, 339, 340, 346,
347, 353, 354, 478, 480,
482
- Pairs statistic
267
- Pairwise tagging
283
- Parent compounds and metabolites
46, 192, 481
- Parkinson's disease (PD)
409–413
- PCR (See Polymerase chain
reaction (PCR))
- Pedigree-based association test
(PBAT)
276, 277
- Penetrance
262–264, 266, 343, 346
- Persistent
bioaccumulative toxics, 460
organic pollutants, 165, 460
- Personalized medicine
100, 123, 126, 304, 319, 496
- Pesticide exposure
413, 480, 482, 487
- Phenotypic sample mean
272
- Phthalates
460
- Phylogenetics
181, 424, 429, 430
- Physical activity
193, 194
- Physicians' health study
193, 399
- Plasmodium
432
- Pneumoconioses
387, 388, 398
- Policy
40, 337, 356, 476, 488, 498
public health and
environmental –, 354
- Polycyclic aromatic hydrocarbons
(PAHs)
67, 72, 171–172, 191, 338, 477,
480, 487
- Polymerase chain reaction (PCR)
66, 74, 432
allele-specific –, 78
measurement of
rearrangements by –,
83–84
multiplex–, 179
mutation-enriched –, 77–78
real-time–, 83, 180
quantitative (Q-PCR) –, 229
single-template –, 89
sensitivity and specificity,
75–76
-RFLP, 181, 392
-single stranded conformation
polymorphism (SSCP),
181
- Polymicrobial infections
436

- Population
 - genetics, 99, 100, 105–107, 292
 - stratification, 105–106, 276, 291–294, 327–329
 - structure, 291–293
 - substructure, 106, 271, 274, 291
 - based case-control studies, 250–255
 - based studies, 250
- Precautionary principle 18
- Pre-eclampsia 459
- Pregnancy outcomes 460–461
- Preventive medicine 303, 305, 317
- Principal component analyses 105–106, 131, 291, 327
- Privacy of subjects 10, 13, 14, 15, 19, 25, 40, 246, 264
- PROCAM risk calculator 375
- Progesterone 204–205, 457–458
- Prognosis and prognostics 308
- Promoter methylation 86, 348–349
- Prospective
 - cohort, 241
 - cohort studies, 245–254, 282, 483, 495–496
 - studies collaboration, 370–373
- Prostate, lung, colorectal and ovarian (PLCO) study 193–194
- Protein
 - biomarker profiles, 413
 - microarrays, 128
 - quantitation, 127–128
- Proteome 122–126, 130, 135, 499
 - human – organization, 27
- Proteomics 28, 121–142, 317, 331, 349–351, 407, 438,
 - applications, 497
- Protocol development 11
- Puberty onset 453–456
- Pubertal status 455
- Public health ethics 18–19
- Publication bias 327, 355
- Q statistic 325
- QRISK 375–376
- Quality
 - assurance, 37, 25, 115, 167
 - control, 25, 37, 90, 104, 110, 113–116, 285–287, 291, 466
 - bioinformatics –, 136
 - genetic data –, 285–287
 - microarray –, 134
- Quantitative phenotypes 265, 272–273
- Quartile-quartile plots (Q-Q plots) 293–294
- Radioimmunoassay (RIA) 48, 129, 183, 199, 208
- Random
 - effects models (*See also* Fixed effects), 326
 - Forest procedure, 297
 - genetic drift, 107
- Randomly amplified polymorphic DNA (RAPD) 181
- Rapid ascertainment of cases 250, 252
- Rapid detection of infectious agents 434
- Recovery biomarkers 190
- Recruiting participants 12, 230, 365, 444, 461, 463
- Recurrence risk 262
 - relative –, 262
- Reliability
 - coefficient, 155–158
 - study, 144, 146–147, 155–159
- Restriction endonuclease analysis 181
- Restriction fragment length polymorphism (RFLP) 75, 77, 108, 181
- Retentate chromatography-mass spectrometry (RC-MS) 124, 128
- Reticulocytes 85
- Reverse phase arrays 128
- Reynolds algorithm 375
- Risk assessment
 - 46, 184
 - individual –, 16, 496
 - and distinct risk profiles, 253
 - and early-life exposures, 465
 - for cancer-causing agent, 57
 - for low level exposures, 352–353, 184
 - of complex diseases, 116
 - process, 44
- Risk prediction algorithms 294, 375–376
- Rolling circle amplification (RCA) 114
- Saliva 30–31, 190, 204–205
 - /buccal cell collection, 30–31
- Sample
 - collection, 23–42, 205–208
 - cost of –, 247
 - feasability of –, 247
 - invasive or complicated –, 461
 - method of –, 249
 - problems in –, 484, 184
 - protocols of –, 349
 - timing of –, 167, 173, 199, 252
 - heterozygosity, 286–287
 - processing, 26, 110, 207
 - size, 153, 154, 283–285
 - in GWAS, 415 (*See also* under Genome-wide)
- Screening cohorts 249
- Security systems for biospecimen facilities 38–39
- Segregation analysis 264–266
- Selection bias 268, 326, 327
 - in case-control studies, 250, 251, 251
- Selective reporting bias 327, 328, 329
- Selenium 191

- Sensitivity
 - beryllium –, 387
 - in error quantification –, 143, 147-150, 159
 - insulin –, 193, 201, 442, 446
 - PCR –, 75-76, 78, 83
 - of analytical techniques, 25, 45, 46, 47
 - of DNA assays, 49, 53, 57, 90, 177, 178, 186
 - of mutation detection, 74-75, 76, 80, 82, 88
 - of omic analyses, 498
- Sequence analysis
 - 104, 110, 113, 115
- Serological methods
 - 176, 182
- Severe acute respiratory syndrome (SARS) (See New infectious agents)
- Severe combined immune deficiency (SCID)
 - 228, 229
- Sex steroids
 - 199, 200
- Short
 - oligonucleotide mass analysis (SOMA), 75, 79
 - tandem repeats (STRs), 105, 285
 - term longitudinal biomarker studies, 242
- Silicosis
 - 393, 394
 - characteristics of –, 392
 - and coal workers' pneumoconiosis, 388, 392, 399
- Single
 - gene disorders, 307
 - nucleotide polymorphisms (SNPs), 101-103, 104, 106, 109, 110, 111
 - the – consortium, 267
 - in GWASs, 123, and microsatellites, 265, (See also dbSNP, tag SNPs)
- Sources of measurement error in biomarkers
 - 144, 145, 147
- Specificity
 - antibody –, 220
 - antigen –, 217, 220, 222
 - assay – and deviation, 106
 - carcinoembryonic antigen test –, 308
 - in error quantification, 143, 147-150, 159
 - method, 87, 88
 - PCR – and sensitivity, 75
 - sequence – of DNA, 177
 - and Hill's criteria, 184
- Specimen
 - collection, 25, 26, 27-39
 - and errors, 145-146, 157, 159, 208
 - and molecular tools, 437
 - and TCDD exposure assessment, 466
 - less-invasive methods of – for children studies, 479
 - processing, 31-32, 146, 176
 - tracking, 35, 37
- Spectral karyotyping (SKY)
 - 83
- Sperm chromatin structure assay (SCSA)
 - 464
- Spontaneous mutations
 - 69, 223, 427
- Spot urine (See Urine)
- Spotted microarrays
 - 124
- Standard operating procedures
 - 33, 35, 36, 37, 106, 114, 179
- Standardization
 - data, 330
 - of terms, 37
 - International Organization for –, 38
 - method –, 46
- Statistical
 - evaluation of interaction, 294-295
 - heterogeneity, 325
 - power, 248, 272, 273, 283, 284, 415
- Storage
 - 23-42, alternate technologies for –, 39
 - at the NCI, 37
 - conditions, 34
 - options, 207-208
 - requirements, 202, 203
 - system maintenance, 34
- STROBE-ME
 - 327
- Study design
 - 11, 169
 - basic principles in –, 281-302
 - common epidemiological –, 447
 - family-based –, 261-280
 - issues in –, 351
 - population-based –, 241-260
- Study results
 - interpreting and communicating –, 15-17
- Subject error
 - 150, 155
- Surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS)
 - 128, 133, 341 (See also Matrix-assisted laser)
- Surrogate endpoint
 - 304, 308
- Surveillance
 - 2, 424-425
 - in outbreak investigation, 428
 - medical –, 391
 - of vaccines, 184
 - population-based – systems, 19
- Survival study
 - 249, 251, 254, 316
- Susceptibility
 - 2, 16
 - biomarkers of –, 44, 45, 193-194, 220, 222
 - in case-control studies, 252
 - loci, 282-283
- System interoperability
 - 36
- Systematic reviews
 - 323, 324-325, 326, 327
 - of published and unpublished studies, 369
- Systematic variation normalization (SVN)
 - 134
- Systems biology
 - 122, 135
 - studies, 378
- Tag SNPs
 - 283, 296
- TagSNPs
 - 103, 104, 109, 290
- Tandem mass spectrometry (MS/MS)
 - 79, 127-129, 498 (See also Mass spectrometry)
- Target tissue
 - 145, 192, 195, 339

- TCDD (*See also* Dioxin)
466–467
half-life, 165
- T-cells
217–218, 223, 224
development, 228
malignancies, 226
helper –, 218, 221
- T-cell receptor (TR)
217, 220, 222
excision circle (TREC), 228
genes, 222
- Technical validation
350
- TEDDY (The Environmental Determinants of Diabetes in the Young)
230–231
- Temporal variability
167
- Testicular dysgenesis syndrome (TDS)
460
- Testosterone
201, 204, 207, 208, 455, 456, 463
- TH1 response
218
- TH2 response
218
- TH17 pathway
218
- The emerging risk factors collaboration (ERFC)
371–373
- Therapeutics
308–310
- Time integration
247
- Tissue
banks, 195, 318
collections, 28–29, 32
- Tobacco smoke
as an exposure marker, 170–172
and lung cancer, 338–340
- Toll-like receptors (TLRs)
221
- Total cholesterol (*See also* Cholesterol, High-density lipoprotein cholesterol, Low-density lipoprotein cholesterol)
370, 371, 375
- Toxic exposures
476, 481, 483, 496
- Toxicogenomics
136, 348, 497
- Transcript profiling
125
- Transcriptome
113, 122, 123, 496, 497
- Transcriptomics
121–142, 317, 319, 438, 496, 497
- Transgenerational health effects
461
- Translational research
310
- Transmission system
425, 427, 436
- Transmission/disequilibrium test (TDT)
268
- Tricarboxylic acid cycle (TCA)
132
- Triglycerides
as a marker of obesity, 441
in literature reviews, 369, 372
in risk prediction algorithms, 375
PUFA in –, 53
- Tumour-associated antigen (TAA)
225–226
- Tumour-specific antigens (TSAs)
225
- Twin registries
261
- Two-dimensional polyacrylamide gel electrophoresis (2D PAGE)
127
- Two-phase sampling design
255
- Two-stage testing strategy
273, 275
- Type 1 diabetes (T1D)
229, 230, 231
- Type 2 diabetes (T2D)
132, 223, 441–452, 477 (*See also* Diabetes, TEDDY)
- Ultra-performance liquid chromatography (UPLC) (*See* Liquid chromatography)
- United Kingdom Biobank
26, 28, 345
Ethics and Governance Framework, 12
study, 378
- U.S. Environmental Protection Agency (EPA)
455
acknowledgement, 356
method standardization, 46
–'s cancer guidelines, 476
- Urinary
mutagenicity, 195, 196
nitrogen, 190, 195
- Urine
collection, 29–30, 190, 457
specimens, 349
24-hour –, 204
morning –, 30, 204, 207
spot –, 202, 204
- Vaccine
422, 426
candidates, 421, 434, 435
induced autism, 468
HPV –, 432
HPV – trial, 39
HBV – trials, 184
programmes, 430
tumour –s, 226
US federal – Injury Compensation Program, 468
- Validity
coefficient, 143, 150–151
of a biomarker test, 155
studies, 11, 143, 144, 150, 154
design of – and reliability studies, 146–147, 155
clinical –, 16
relation of reliability to –, 156–157
- Variation
coefficient, 158
- Venice criteria
328, 345
- Vitamin C
191
- Vitamin D
191
–/calcium-related pathway genetics, 194
metabolites, 200
receptor, 209
association of – and several cancer sites, 351
variation of – concentrations, 206
- Vitamin E
191
- Waist
circumference, 445, 448
to-height ratio, 448
- West Nile virus
encephalitis, 433
and dengue, 422
in the United States, 427, 433
- White blood cells (WBC)
50, 202, 203, 218, 249, 253, 339, 480, 481

Whole-genome
 amplification (WGA), 30, 109,
 114, 248,
 research, 13, 19-20, 110, 123,
 124, 276, 285

Windows of susceptibility
 456, 465

Within-person variability
 195
 biomarker –, 159, 246, 247, 370
 over time, 208

Xenobiotic
 131, 464
 chemicals, 230
 metabolism, 398, 494
 activation and detoxification
 of –s, 478
 exposure to a –, 16, 43, 44,
 242, 464
 markers of –, 304

X-ray fluorescence (XRF)
 46, 410

Zinc
 195, 196
 superoxide dismutase, 410